Explore or download the report by clicking on the image above or here.
Decentralized clinical trials have had the potential to revolutionize studies for a number of years, though in the last two years, accelerated by COVID-19, they have finally started to realise some of that potential.
However, to what extent have decentralized trials – and associated elements of Home Trial Support (home trial HcP/nurse visits and VCT/remote technology) – been adopted in the industry? And what are the true impacts on speed, patient recruitment and retention, cost and patient-centricity?
Clinical Trials Europe in partnership with MRN, conducted a huge survey of clinical trials professionals around the world to answer these questions. This final report based on 125 responses reveals unique insights into the adoption of decentralized trials today, introduced by MRN CEO Grahm Wylie.
Key Insights
- 70% of respondents have been involved in or worked on trials that have implemented some decentralized element in the last two years.
- 58% say decentralized trials are faster than traditional trials in their experience, saving respondents on average just under 3 months to completion.
- 71% say decentralized trials are better for patient recruitment than traditional trials, and 74% for retention.
- 81% say decentralized trials cost about the same or have a lower overall cost than traditional trials.
Explore or download the report by clicking on the image above or here.